Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation

Abstract Giant cell tumor of bone (GCTB) is a locally aggressive lesion of intermediate malignancy. Malignant transformation of GCTB is a rare event. In 2013, the humanized monoclonal antibody against receptor activator of nuclear factor-κb-Ligand (RANKL) denosumab was approved for treatment of adva...

Full description

Saved in:
Bibliographic Details
Main Authors: Marc Hasenfratz, Kevin Mellert, Ralf Marienfeld, Alexandra von Baer, Markus Schultheiss, P. D. Roitman, L. A. Aponte-Tinao, Burkhard Lehner, Peter Möller, Gunhild Mechtersheimer, Thomas F. E. Barth
Format: article
Language:EN
Published: Nature Portfolio 2021
Subjects:
R
Q
Online Access:https://doaj.org/article/7e362e1fc5aa4bdcbb09fa7a3c4adf92
Tags: Add Tag
No Tags, Be the first to tag this record!